Viola Salvestrini, Kyubo Kim, Saverio Caini, Sara Alkner, Maria Ekholm, Tanja Skyttä, Carlotta Becherini, Charlotte E Coles, Orit Kaidar-Person, Birgitte Offersen, Evandro de Azambuja, Luca Visani, Javier Cortes, Nadia Harbeck, Hope S Rugo, Clare M Isacke, Elisabetta Marangoni, Andrea Morandi, Matteo Lambertini, Philip Poortmans, Lorenzo Livi, Icro Meattini
BACKGROUND AND PURPOSE: In recent years, the treatment landscape for breast cancer has undergone significant advancements, with the introduction of several new anticancer agents. One such agent is trastuzumab emtansine (T-DM1), an antibody drug conjugate that has shown improved outcomes in both early and advanced breast cancer. However, there is currently a lack of comprehensive evidence regarding the safety profile of combining T-DM1 with radiation therapy (RT). In this study, we aim to provide a summary of the available data on the safety of combining RT with T-DM1 in both early and metastatic breast cancer settings...
September 2023: Radiotherapy and Oncology